Neuropilin-1 (NRP1) and neuropilin-2 (NRP2) are transmembrane glycoproteins with large extracellular domains that interact with class 3 semaphorins, vascular endothelial growth factor (VEGF) family members, and ligands, such as hepatocyte growth factor, platelet-derived growth factor BB, transforming growth factor-b1 (TGF-b1), and fibroblast growth factor2 (FGF2). Neuropilins (NRPs) have been implicated in tumor growth and vascularization, as novel mediators of the primary immune response and in regeneration and repair; however, their role in renal pathophysiology is largely unknown. Here, we report upregulation of tubular and interstitial NRP2 protein expression in patients with focal segmental glomerulosclerosis (FSGS). In an additional cohort of patients with minimal change disease (MCD), membranous nephropathy (MN), and FSGS, elevated NRP2 mRNA expression in kidney biopsies inversely correlated with estimated glomerular filtration rate (eGFR) at the time of biopsy. Furthermore, upregulation of NRP2 mRNA correlated with post-bioptic decline of kidney function. Expression of NRP1 and NRP2 in human proximal tubular cells (PTCs) was differentially affected after stimulation with TGF-b1, interleukin-1b (IL-1b), and oncostatin M (OSM). Although the pro-fibrotic mediators, TGF-b1 and IL-1b, induced upregulation of NRP2 expression but downregulation of NRP1 expression, OSM stimulated the expression of both NRP1 and NRP2. Basal and OSM-induced NRP1 mRNA expression, as well as TGF-b1-induced NRP2 mRNA and protein expression were partially mediated by MEK1/2-ERK1/2 signaling. This is the first report suggesting a differential role of NRP1 and NRP2 in renal fibrogenesis, and TGF-b1, IL-1b, and OSM represent the first ligands known to stimulate NRP2 expression in mammalian cells.
In contrast to the well-studied neuronal and vascular system, neuropilin (NRP) expression in cells of epithelial origin has received little attention so far. As epithelial cells in the breast, uterus, endometrium, kidney, and lung do express neuropilin-1 (NRP1), it is not surprising that tumors of epithelial origin show strong expression of this NRP isoform.
1,2 NRP1 is highly expressed in carcinoma cell lines, such as prostatic and breast carcinoma cells, transitional cell, and renal cell carcinoma cells. 3 In contrast, neoplasms of non-epithelial origin, such as human melanoma cells or human glioblastoma cells, show little NRP1 expression but high neuropilin-2 (NRP2) expression. 3 NRP2 has recently been shown to have a critical and direct role in colorectal carcinoma tumor progression and may represent a potential therapeutic target for cancers in which it is expressed. 4 Very little information is available regarding NRP expression and its regulation in renal tubular epithelial cells. NRP1 mRNA and protein expression has been detected in whole kidney, single and sieved glomeruli, as well as in cultured visceral glomerular epithelial cells. 5 Furthermore, mRNA expression of NRP1 and NRP2 was observed in immortalized murine inner medullary collecting duct cells and mouse proximal tubular cells (PTCs). 6 In these tubular epithelial cells, vascular endothelial growth factor (VEGF)-induced branching morphogenesis and tubulogenesis was VEGFR2-and NRP1-dependent, suggesting that, in addition to endothelial vas-culogenesis, VEGF can induce renal epithelial cell morphogenesis in a NRP1-dependent fashion. 6 Very recently it has been shown that advanced glycation end-products suppress NRP1 expression in podocytes, and that NRP1 expression is decreased in glomeruli of diabetic db/db mice when compared with their nondiabetic littermates. 7 Finally, transcripts of both NRPs were found to be decreased in renal biopsies from patients with diabetic nephropathy compared with transplant donors. 7 Here, we studied expression of NRP1 and NRP2 in tissue sections of patients with focal segmental glomerulosclerosis (FSGS) and different levels of tubulointerstitial fibrosis, as well as in human PTCs stimulated with the pro-fibrotic mediators transforming growth factor-b1 (TGF-b1) and interleukin-1b (IL-1b). Immunofluorescence analysis of FSGS tissue showed upregulation of tubular and interstitial NRP2 expression in fibrotic kidneys. In an additional cohort of patients with minimal change disease (MCD), membranous nephropathy (MN), and FSGS, elevated NRP2 mRNA expression in kidney biopsies correlated with post-bioptic decline of kidney function. Furthermore, the pro-fibrotic mediators, TGF-b1 and IL-1b, induced upregulation of NRP2 expression but downregulation of NRP1 expression, whereas the interleukin-6 family member oncostatin M (OSM) stimulated expression of both NRP1 and NRP2. Basal and OSM-stimulated NRP1 mRNA expression, as well as TGF-b1-induced NRP2 expression was partially U0126-and Cl-1040-sensitive, suggesting that the MEK1/2-ERK1/2 signaling module is involved in these effects. Together, these results suggest a differential role of NRP1 and NRP2 in human renal fibrogenesis and represent the first description of ligands, such as TGF-b1, IL-1b, and OSM, which are able to stimulate NRP2 expression in mammalian cells.
MATERIALS AND METHODS Reagents
Cell culture reagents were obtained from Gibco (Life Technologies, Lofer, Austria). U0126 was purchased from Calbiochem (Nottingham, UK) and Cl-1040 was kindly provided by P Cohen (MRC Protein Phosphorylation Unit, University of Dundee, Dundee, UK). Recombinant human OSM was obtained from Sigma (St Louis, MO, USA), whereas recombinant human TGF-b1 and recombinant human IL-1b were purchased from R&D Systems. All other reagents were obtained from Sigma.
Cell Culture
Human PTCs human kidney-2 (HK-2) were cultured in Keratinocyte-Serum Free Medium (KSFM) containing 10% fetal bovine serum (FBS), 5 ng/ml recombinant epidermal growth factor (rEGF), 0.05 mg/ml bovine pituitary extract, 100 units/ml penicillin, and 100 mg/ml streptomycin. [8] [9] [10] The cells (passages [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] were grown at 371C in a humidified 5% CO 2 atmosphere, and split at a 1:10 ratio, once a week. After growth to a subconfluent state, cells were washed once, made quiescent by incubation in serum-and supplementfree medium for 48 h, and then used for experiments. Stimulations with ligands, such as OSM, TGF-b1 and IL-1b, or combinations thereof were performed in the absence of serum and any other growth supplements.
Western Blot Analysis
Cells were washed with ice-cold phosphate buffered saline (PBS) and lysed in 1 Â Laemmli buffer. 10 For the examination of ERK1/2 phosphorylation and ERK2 protein expression, cells were lysed in ice-cold RIPA lysis buffer as described previously. 10 Insoluble material was removed by centrifugation at 12 000 g for 15 min at 41C. The protein concentrations were determined using a microbicinchoninic acid assay (Pierce) or Coomassie protein assay (Pierce) with BSA as a standard. Cell lysates were matched for protein, separated by 10% SDS-PAGE, and transferred to a polyvinylidene difluoride microporous membrane. Subsequently, membranes were probed with one of the following specific antibodies: anti-NRP1 (A-12) mouse monoclonal antibody, anti-NRP2 (C-9) mouse monoclonal antibody, anti-ERK2 (C-14) goat polyclonal antibody (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-b-actin mouse monoclonal antibody (Sigma), anti-phospho-p44/42 MAPK (ERK1/2) Thr202/Tyr204 rabbit polyclonal antibody (Cell Signaling Technology, Beverly, MA, USA). After extensive washing of the sheets in TBS, 0.1% Tween-20, the primary antibodies were detected using horseradish peroxidaseconjugated goat anti-mouse IgG, rabbit anti-goat IgG, or goat anti-rabbit IgG (all from Santa Cruz Biotechnology), and visualized by ECL Plus Western Blotting Detection system (GE Healthcare, Buckinghamshire, UK) or by LumiGLO Western Blot Detection system (Cell Signaling Technology).
Renal Biopsies
We used 20 kidney biopsies obtained from patients with nephrotic kidney diseases during their routine diagnostic workup for which we had sufficient clinical follow-up data ( Table 3 ). The histological diagnoses were MCD (n ¼ 8), MN (n ¼ 7), and FSGS (n ¼ 5). Renal function was assessed at two time points by calculating the estimated glomerular filtration rate (eGFR) using the MDRD formula. The median followup time was 25 months (12-32 months). Patients were defined stable (n ¼ 13) when eGFR was 460 ml/min/1.73 m 2 at both time points, or when eGFR was o60 ml/min/1.73 m 2 at either time point, and DeGFR was higher than À1 ml/min/ 1.73 m 2 per year. Patients were defined as progressive (n ¼ 7) when eGFR was 460 ml/min/1.73 m 2 at the time of biopsy and o60 ml/min/1.73 m 2 during follow-up, or when eGFR was o60 ml/min/1.73 m 2 at both time points and DeGFR was oÀ1 ml/min/1.73 m 2 per year, or when they reached end-stage renal disease. RNA was isolated using Qiagen RNeasy Mini kit (Qiagen, Valencia, CA, USA), the samples were preamplified using TaqMan PreAmp Master Mix (Ambion, Austin, TX, USA) together with the respective TaqMan probes (vide infra) for B400-fold amplification of the original RNA. The accuracy of this amplification method was tested, and we did not find any amplification bias (data not shown). In all biopsy real-time PCR experiments, we used PPIA (cyclophilin A; Hs99999904_m1) as an endogenous control. The use of surplus material for research purposes after routine diagnostic workup was approved by the Institutional Review Board of the Innsbruck Medical University.
RNA Isolation and Real-Time PCR Analysis
Total cellular RNA was extracted using TRI Reagent (Molecular Research Center, Cincinnati, OH, USA). 9 RNA quantity was estimated by spectrophotometric analysis. Reverse transcription was carried out in 20 ml volume using 2 mg total RNA, 1 mM random hexanucleotides as primer (Roche Diagnostics, Indianapolis, IN, USA), and Omniscript Reverse Transcriptase (Qiagen) according to the manufacturer's instructions. The reaction was carried out in RNase-free condition at 371C for 60 min and heated at 931C for 5 min to inactivate RTase. The cDNA was stored at À201C until use in TaqMan Gene Expression Assays (Applied Biosystems).
PCR was carried out using 2 ml of cDNA template from the RT reaction, 1 Â TaqMan Universal PCR Master Mix containing dNTPs, AmpErase UNG, and AmpliTaq Gold DNA polymerase (Applied Biosystems), and premade TaqMan Gene Expression Assay Mix consisting of FAM dye-labeled TaqMan MGB probe and unlabeled PCR primers for human NRP1 (Hs00826129_m1), for human NRP2 (Hs00187290_m1), or for human VEGF-A (Hs00173626_m1), respectively (Applied Biosystems). 9 Thermal cycler conditions were as follows: 501C for 2 min and 951C for 10 min, followed by 45 cycles of amplification at 951C for 15 s and 601C for 1 min. All reactions were run in duplicate. Each amplification experiment was carried out in a 96-well PCR plate on an ABI 7500 Sequence Detection System. All cellular RNA samples were normalized based on the TaqMan Gene Expression Assays for human GAPDH (Hs99999905_m1). Relative changes in gene expression (fold change) were calculated using the 2 ÀDDCT method.
Indirect Immunofluorescence
Human PTCs were grown to subconfluence on chamber slides (Lab-tek) and starved for 24 h. Next, cells were stimulated with TGF-b1 at a concentration of 10 ng/ml for 24, 48, and 72 h. Controls were grown in regular DMEM medium. After the end of the stimulation period, cells were washed three times with PBS and fixed with methanol/acetone (1:1) at À201C for 20 min. Cells were subsequently washed three times with PBS, and blocked with 1% BSA in PBS for 1 h. Wells were incubated with the anti-NRP1 or anti-NRP2 antibody (at a concentration of 1:25) for 1 h at 371C, washed three times with PBS, and incubated with the rhodamineconjugated Fab secondary antibody (dilution 1:100, Chemicon, Hofheim, Germany) for 1 h at 371C. Nuclei were counterstained with DAPI (dilution 1:1000 of a stock of 1 mg/ml).
After washing three times with PBS, cells were mounted by DAKO fluorescence mounting medium (DAKO, Hamburg, Germany). Visualization was performed using an Olympus IX10 fluorescence microscope. For NRP1 and NRP2 expression studies in renal tissue, eight kidney sections from biopsies from patients with FSGS and variable degrees of tubulointerstitial fibrosis were stained. Kidney sections from non-tumor parts of tumor nephrectomies served as controls. Stainings were performed by indirect immunofluorescence. Briefly, paraffin sections were deparaffinized followed by blocking with 3% H 2 O 2 for 15 min. Incubation with the primary antibodies (anti-NRP1 and anti-NRP2, both 1:200) was followed by incubation with the Rhodamine-labeled secondary antibody (Chemicon) at a dilution of 1:500. Before analysis, nuclei were counterstained with DAPI (dilution of 1:1000 of a 1 mg/ml stock solution). Specificity of antibody labeling was shown by the lack of staining after substituting proper control immunoglobulins for the primary antibodies. Slides were mounted with DAKO fluorescent mounting medium (DAKO) and images were visualized using an Olympus IX10 fluorescence microscope. Tubular stainings were classified by two independent investigators who had been blinded for the diagnosis and staining performed as negative (+), positivity in o25% of tubuli ( þ ), staining of 25-50% of tubuli ( þ þ ), and positivity of 450% of tubuli ( þ þ þ ). In addition, staining patterns were noted. The use of kidney biopsies for research purposes was approved by the local ethics committee of the University of Goettingen, and written consent was obtained from all patients before biopsy.
Statistical Analyses
Pearson's R and a two-tailed t-test were used for calculation of correlation between real-time PCR results of NRP1 and NRP2 mRNA expression in the renal biopsies, the eGFR at the time of biopsy, and the decline of eGFR during follow-up, respectively. Two-tailed t-tests were used to assess the significance of differences of ligand and inhibitor administration on the mRNA expression in human PTC when compared with untreated cells. Fold alterations in mRNA levels are expressed as mean±s.e.m.
RESULTS

Upregulation of Endoluminal and Interstitial NRP2 Expression in Human FSGS
As preliminary real-time PCR analyses of microdissected PTC obtained from patients with a progressive loss of kidney function revealed alterations in NRP expression, we decided to carry out immunofluorescence analysis of NRP1 and NRP2 expression in tissue sections from FSGS patients (n ¼ 8) with variable degrees of tubulointerstitial fibrosis when compared with expression levels in normal control kidneys (n ¼ 3). Clinical characteristics of FSGS patients and controls are summarized in Table 1 . As depicted in Figure 1b , basal NRP1 protein expression in control kidneys was FSGS, focal segmental glomerulosclerosis. Figure 2d ). Although tubular staining was mainly detected in PTC, interstitial staining seemed to be localized mainly to interstitial fibroblasts. Moreover, atrophic tubules and morphologically unchanged tubules displayed increased NRP2 staining. This increased NRP2 expression seemed to be associated with a tendency towards the downregulation of tubular NRP1 expression in FSGS kidneys when compared with control kidneys (Table 2) . A semi-quantitative analysis of all the experiments in eight FSGS patients and three control kidneys is summarized in Table 2 . These results suggest that the two NRP isoforms are differentially expressed in FSGS patients with variable degrees of tubulointerstitial fibrosis when compared with those of normal control kidneys.
Increased NRP2 mRNA Expression in Nephrotic Kidney Diseases Correlates Inversely with eGFR at the Time of Biopsy and is Associated with Adverse Renal Prognosis
To validate these findings, we analyzed mRNA expression of NRP1 and NRP2 in 20 additional kidney biopsies from patients with nephrotic kidney diseases, such as MCD, MN, and FSGS (Table 3 and Figure 3 ). mRNA expression of NRP2, but not of NRP1, showed a significant correlation with renal function (expressed as eGFR) at the time of biopsy (Figure 3a) . Patients with impaired renal function showed higher NRP2 mRNA expression, whereas patients with near normal renal function showed low NRP2 mRNA values (Figure 3a) . Furthermore, we analyzed the correlation of NRP1 and NRP2 mRNA levels with the clinical follow-up of these patients. Although NRP1 mRNA showed higher expression in progressive patients when compared with stable nephrotic diseases, this difference did not reach significance (1.4-fold; P ¼ 0.08). However, NRP2 was significantly upregulated in those patients who showed a decline of renal function during the median follow-up period of 25 months (1.7-fold; P ¼ 0.04) (Figure 3b ). These results suggest that an increased mRNA expression of NRP2, but not of NRP1, predicts poor renal outcome in various renal nephrotic pathologies already at the time of biopsy.
The Pro-Fibrotic Mediators, TGF-b1 and IL-1b, Inhibit NRP1 Expression But Stimulate NRP2 Expression in Human Proximal Tubular Cells Among the many factors that regulate the renal fibrotic process, TGF-b1 is one that have a central role. [11] [12] [13] [14] Other factors, such as IL-1b, can regulate epithelial-mesenchymal transition (EMT) and fibrosis through modulation of TGF-b1 expression or activity, 15 or in the case of OSM, have potential to act as both a pro-EMT molecule and a pro-MET mediator. 10 As human kidneys with various degrees of tubulointerstitial fibrosis showed robust upregulation of tubular and interstitial NRP2 protein expression, we investigated the effects of pro-fibrotic mediators TGF-b1 and IL-1b when compared with OSM in human PTCs in culture. A 24 h stimulation of human PTC with TGF-b1 (10 ng/ml) or IL-1b (10 ng/ml) led to a partial inhibition of NRP1 mRNA expression and a strong induction of NRP2 mRNA levels ( Figure 4a ). When compared with unstimulated controls, TGF-b1-and IL-1b-induced NRP2 mRNA expression was 4.8-fold and 3.5-fold, respectively (n ¼ 4; Po0.01). In contrast, 10 ng/ml OSM stimulated both NRP1 and NRP2 mRNA expression 1.8-and 2.2-fold, respectively (Figure 4a ; n ¼ 4, Po0.01). All three cytokines of interest induced VEGF-A mRNA expression in human PTC after 24 h (Figure 4a ). These results from real-time PCR were verified by western blot analysis. After 48 h of incubation, TGF-b1 and IL-1b inhibited NRP1 protein expression but stimulated NRP2 protein expression (Figure 4b ), whereas OSM increased both NRP1 and NRP2 protein levels (Figure 4b) . Administration of IL-1b together with TGF-b1 revealed an additive inhibitory effect on NRP1 protein expression (data not shown). The effects of TGF-b1 and IL-1b on NRP1 and NRP2 mRNA expression were time dependent. TGF-b1-mediated inhibition of NRP1 mRNA expression started after 12 h and reached significance after 48 h of incubation (Figure 5a ; n ¼ 5, Po0.05). IL-1b led to a similar, albeit not significant tendency towards inhibition of NRP1 mRNA expression (Figure 5a ; n ¼ 5, P ¼ 0.056 after 48 h of incubation). TGF-b1-and IL-1b-stimulated NRP2 mRNA expression showed similar kinetics (Figure 5b ) as did the OSMinduced VEGF-A mRNA expression (data not shown). After 48 h of stimulation, TGF-b1 and IL-1b led to a 6.3-and a 3.2-fold increase in NRP2 mRNA expression, respectively (Figure 5b ; n ¼ 5, Po0.01). TGF-b1-mediated effects on NRP1 and NRP2 protein expression showed a similar time dependence (Figure 5c ). Both TGF-b1-inhibited NRP1 protein expression and TGF-b1-stimulated NRP2 protein expression started as early as 6 h after incubation and showed 
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a maximum effect after 48 h. All together these results suggest that in human PTC in culture the two pro-fibrotic mediators, TGF-b1 and IL-1b, represent strong stimulators of NRP2 expression but inhibitors of NRP1 expression. In contrast, the IL-6 family member OSM seems to induce expression of both NRP2 and NRP1.
These results were corroborated by immunofluorescence studies showing that NRP2 was not detectable in human PTC in culture under basal conditions (Figure 6a ) and that NRP1 expression was not inducible by stimulation with 10 ng/ml TGF-b1 (Figure 6b) . Conversely, the expression of NRP2 was inducible by TGF-b1 in a time-dependent manner peaking after 48 (Figure 6c ) and 72 h (Figure 6d) . Interestingly, NRP2 expression was restricted almost exclusively to cells undergoing mitosis. In summary, TGF-b1, IL-1b, and OSM represent the first mediators known to affect NRP2 expression in mammalian cells. Moreover, these findings are the first evidence for a differential regulation of NRP1 and NRP2 mRNA expression in cytokine-stimulated renal tubular epithelial cells of human origin and support the idea of a differential role of both NRPs in renal tubulointerstitial fibrogenesis.
TGF-b1-Induced NRP2 mRNA and Protein Expression is MEK1/2-ERK1/2 Dependent
In addition to the canonical Smad signaling pathways that are known to have a role in the regulation of cell growth, differentiation and TGF-b-induced EMT, Smad-independent TGF-b-regulated networks are known to include Ras-Raf-MEK-ERK signaling. 16 Cooperative signaling between TGF-b1 and MEK1/2-ERK1/2 is required for the maintenance of complete EMT in various epithelial cell types, 17, 18 and OSM is a strong stimulator of the mitogen-activated protein kinases, ERK1, ERK2, and ERK5, in human PTC. 10 Thus, we investigated the regulatory function of the intracellular signaling molecules ERK1 and ERK2 for NRP1 and NRP2 expression in OSM-when compared with TGF-b1-stimulated human PTC. Preincubation of human PTC with 10 mM of the synthetic MEK1/2 inhibitor U0126 slightly inhibited basal and OSM-induced NRP1 mRNA expression after 24 h (n ¼ 6, Po0.05), but did not affect TGF-b1-and IL-1b-mediated inhibition of NRP1 mRNA expression (Figure 7a ). In contrast, 10 mM U0126 partially inhibited TGF-b1-induced NRP2 mRNA expression in human PTC from a 3.85-± 0.35-fold increase in the absence of U0126 to a 2.63-± 0.13-fold increase in the presence of U0126 (Figure 7b ; n ¼ 6, Po0.01). Similar results were obtained using 1 mM of the MEK1/2 inhibitor Cl-1040, which partially inhibited TGF-b1-induced NRP2 protein expression without having an effect on basal NRP2 protein expression (Figure 7c ). In parallel, the synthetic MEK1/2 inhibitor Cl-1040 (PD184352) completely inhibited ERK1/2 phosphorylation in the absence and in the presence of OSM or TGF-b1 after 24 h of incubation without affecting ERK2 protein expression (Figure 7c) . Furthermore, Cl-1040 inhibited rapid OSM-induced ERK1/2 phosphorylation after 10 min of stimulation (Figure 7c) . At a concentration of 1 mM, Cl-1040 has previously been reported to inhibit basal and EGF-induced ERK1/2 phosphorylation, but not ERK5 phosphorylation in human PTC. 17 Thus, these results suggest that OSM-induced NRP1 mRNA expression and TGF-b1-induced NRP2 mRNA and protein expression is partially mediated by MEK1/2-ERK1/2 signaling.
DISCUSSION
Our study shows four novel findings with respect to a pathophysiological role of NRP isoforms 1 and 2 and their regulation in human kidneys: (i) Tubular and interstitial NRP2 expression is upregulated in human FSGS kidneys with variable degrees of tubulointerstitial fibrosis. (ii) Increased NRP2 mRNA expression in separate kidney biopsies from patients with nephrotic kidney diseases correlates inversely with eGFR at the time of biopsy and is associated with adverse renal prognosis. (iii) NRP1 and NRP2 expression in human PTC is differentially affected by the pro-fibrotic cytokines TGF-b1 and IL-1b when compared with the IL-6 family member OSM. TGF-b1 and IL-1b induce upregulation of NRP2 expression and downregulation of NRP1 expression in human PTC. (iv) OSM-stimulated NRP1 mRNA expression and TGF-b1-stimulated NRP2 expression are U0126-and Cl-1040-sensitive suggesting that these effects are at least partially mediated by the MEK1/2-ERK1/2 signaling pathway.
NRP1 was originally identified as a neuronal cell surface protein. 19 Subsequently, analysis of NRP1 transgenic and MCD, minimal change disease; pFSGS, primary focal-segmental glomerulosclerosis; MN, membranous nephropathy. Interstitial fibrosis was scored as none, mild (o10%), moderate (10-30%) and severe (430 %).
We analyzed NRP1 and NRP2 mRNA expression in 20 kidney biopsies from patients with nephrotic kidney diseases. deficient mouse and zebrafish models established an essential role of NRP1 in the development of the embryonic nervous and cardiovascular systems. [20] [21] [22] [23] NRPs are also highly expressed in diverse tumor cell lines and human neoplasms and have been implicated in tumor growth and vascularization. [2] [3] [4] 24, 25 More recently, it has been reported that NRP1 might have a role as a novel mediator of the primary immune response, as well as in tissue regeneration and repair. 26 Together these findings suggest that NRPs are multifunctional co-receptors essential for neuronal and cardiovascular development, but potentially have additional functions in diverse physiological and disease-related settings. Thus, and on the basis of the preliminary real-time PCR analyses of microdissected proximal tubular cells from patients with a progressive loss of kidney function, it was of interest to us to study the expression of the two NRP isoforms in renal tissue sections of patients suffering from FSGS. Interestingly, these experiments revealed reduced luminal NRP1 expression associated with the upregulation of endoluminal and interstitial NRP2 expression in human FSGS. These results were corroborated by the finding of an inverse correlation of increased NRP2 mRNA expression with impaired renal function at the time of biopsy and with adverse renal outcome in various nephrotic kidney diseases, such as MCD, MN, and FSGS. Hence, an increased expression of NRP2 mRNA may predict poor renal outcome in renal nephrotic pathologies already at time of biopsy.
Differential neuropilin expression in FSGS
Clinical studies suggest that NRP1 has a role in tumor growth and disease progression. 3, 25, 27 Overexpression of NRP1 has been shown to be positively associated with the metastatic potential, advanced stage, and clinical grade of prostate carcinoma. 28 NRP1 upregulation in gastrointestinal carcinomas seems to correlate with invasive behavior and metastatic potential. 29 Co-expression of NRP1 and NRP2 also increased in the progression from dysplasia to microinvasive lung carcinoma, and correlated significantly with tumor progression and poor prognosis in patients with nonsmall-cell lung carcinoma. 30 Although most studies have indicated a pro-tumorigenic role of NRPs, some reports suggest that NRP1 has a more complex role in some tumor types. NRP1 overexpression in Panc-1 cells was found to reduce tumor volume and incidence, 31 and there is also evidence pointing to potentially differential or antagonistic roles of NRP1 and NRP2 in tumor cell regulation. 27 In agreement with murine studies, data from human surgical wounds indicate endothelial NRP1 upregulation early in the wound-healing process, that is, by 2 weeks after injury. 26 Thereafter, NRP1 expression is downregulated as tissue repair continues. To date there is no evidence that NRP2 has a role in wound healing. 26 In contrast to these reports, very little is known about a possible physiological or pathophysiological role of NRPs in the kidney. In embryonic rat and mouse kidneys, NRP1 and especially NRP2 are several fold more abundant than in Patients were defined as stable (n ¼ 13) or progressive (n ¼ 7) according to loss of eGFR during follow-up as described in section Materials and Methods. NRP1 mRNA expression showed a tendency to higher values in progressive patients (P ¼ 0.08), whereas NRP2 mRNA was significantly (P ¼ 0.04) upregulated in progressive patients (*Po0.05).
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newborn or adult kidneys. 32 In immortalized murine inner medullary collecting duct cells, and mouse PTC, VEGF-induced branching morphogenesis and tubulogenesis was VEGFR2-and NRP1-dependent, suggesting that, in addition to endothelial vasculogenesis, VEGF might induce renal epithelial cell morphogenesis in a NRP1-dependent manner. 6 Furthermore, a significant decrease in the percentage of NRP1-positive cells among lymphocytes was found in rejected kidney graft biopsies, which might point to a potential role of NRP1 in predicting the immune state of kidney grafts as a marker of regulatory T cells. 33 Very recently it has been shown that advanced glycation end-products suppress NRP1 expression in mouse podocytes and that NRP1 expression is decreased in glomeruli of diabetic db/db mice when compared with their nondiabetic littermates. 7 Finally, transcripts of both NRPs were found to be decreased in renal biopsies from patients with diabetic nephropathy when compared with transplant donors. 7 Here, we report the upregulation of tubular and interstitial NRP2, but not of NRP1 expression in human FSGS, suggesting for the first time a differential role of the two NRP isoforms in tubulointerstitial fibrogenesis. This idea is further supported by our observed effects of the two cytokines, TGF-b1 and IL-1b, on NRP1 and NRP2 expression in human PTC. It is widely accepted that TGF-b1 and its downstream signaling has an essential role in tissue fibrosis in general and in renal fibrosis in particular. Besides that TGF-b1 and IL-1b also represent well established stimulators of renal tubular EMT, a phenotypic conversion of mature tubular epithelial cells towards (myo)fibroblasts that is fundamentally linked to the pathogenesis of renal interstitial fibrosis. [11] [12] [13] Hence these ligands, together with other cytokines such as platelet-derived growth factor or fibroblast [34] [35] [36] [37] [38] [39] [40] In contrast, no stimulators of NRP2 expression have been published so far. 3, 26 As additional mechanisms that favor the maintenance of an epithelial architecture, such as those driving MET, must exist in a healthy renal proximal tubular system, even in response to tubular injury, cellular mechanisms acting in both directions might be turned on. 10 Indeed, it has been speculated that OSM may represent a cytokine that has the ability to act as both a pro-EMT molecule and a pro-MET mediator depending on the tubular epithelial cell microenvironment and/or the specific injury. 10 In this context, it is of interest that the IL-6 family member OSM stimulates both NRP1 and NRP2 expression in human PTC, in contrast to the two established pro-fibrotic mediators, TGF-b1 and IL-1b. Both OSM-induced NRP1 expression and TGF-b1-induced NRP2 expression seem to be partially mediated by MEK1/2-ERK1/2 signaling. Indeed, major signal transduction pathways that induce EMT include Smad signaling, PI3K, the mitogenactivated protein kinases ERK1/2, and STAT signaling. 18, 41 Especially in the renal tubular system, strong evidence exists for an important function of the MEK1/2-ERK1/2 signaling module in EMT. 10, [42] [43] [44] Furthermore, it has been reported that OSM represents a strong stimulator of both ERK1/2 and STAT1/3 signaling in human PTC. 10 In summary, the final functional cellular outcome of differential NRP isoform expression in renal cells such as tubular epithelial cells or tubulointerstitial fibroblasts could be controlled by gradients of extracellular ligands, by coexpression of signaling receptors, such as plexins or VEGFRs, and by ligands acting through NRPs and their co-receptors. protein expression, and of ERK1/2 phosphorylation in human PTC, which were serum-and supplement-starved for 48 h, and were then stimulated with OSM (10 ng/ml) or TGF-b1 (10 ng/ml) for 24 h either in the absence (+ Cl-1040) or in the presence ( þ Cl-1040) of the synthetic MEK1/2 inhibitor Cl-1040 (1 mM). As an additional, positive control human PTC were stimulated for 10 min with OSM in the absence and in the presence of Cl-1040 (PD184352). Protein-matched samples of whole cell lysates (for NRP1, NRP2, b-actin) and soluble lysates (for p-ERK1/2 and ERK2) were separated on SDS-PAGE and analyzed by western immunoblot for protein expression of NRP1, NRP2, b-actin, phosphorylated-ERK1/2 (p-ERK1/2), and ERK2. The results from one representative western blot of n ¼ 4 independent experiments are depicted.
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